Silo Pharma, Inc.

We are a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company. Our therapeutic focus is on developing novel therapeutics that address underserved conditions including PTSD, stress-induced anxiety disorders, fibromyalgia, and central nervous system (CNS) diseases. We are focused on developing novel therapies that include conventional drugs and psychedelic formulations. The Company’s lead program, SPC-15, is an intranasal drug targeting PTSD and stress-induced anxiety disorders. SP-26 is a time-release ketamine-based loaded implant for fibromyalgia and chronic pain relief. Silo’s two preclinical programs are SPC-14, an intranasal compound for the treatment of Alzheimer’s disease, and SPU-16, a CNS-homing peptide targeting the central nervous system with initial research indication in multiple sclerosis (MS).

Current securities

1. 10-Q filingNov 13, 2026
2. Entry into a Material Definitive Agreement · Unregistered Sales of Equity SecuritiesNov 6, 2026
3. Entry into a Material Definitive Agreement · Unregistered Sales of Equity SecuritiesOct 14, 2026
4. Entry into a Material Definitive Agreement · Unregistered Sales of Equity SecuritiesOct 2, 2026
5. Entry into a Material Definitive Agreement · Unregistered Sales of Equity SecuritiesAug 19, 2026